Patents by Inventor Gerard Sanacora

Gerard Sanacora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20240033254
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 1, 2024
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Combination therapy for treating or preventing depression or other mood diseases
    Patent number: 11793794
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: October 24, 2023
    Assignees: YALE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20230070600
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 9, 2023
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • Glutamate agents in the treatment of mental disorders
    Patent number: 11554117
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: January 17, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20210294011
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 23, 2021
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Combination Therapy for Treating or Preventing Depression or Other Mood Diseases
    Publication number: 20210251969
    Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
    Type: Application
    Filed: August 20, 2019
    Publication date: August 19, 2021
    Inventors: Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20210093630
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: December 7, 2020
    Publication date: April 1, 2021
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20180318288
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: July 10, 2018
    Publication date: November 8, 2018
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Glutamate agents in the treatment of mental disorders
    Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • GLUTAMATE AGENTS IN THE TREATMENT OF MENTAL DISORDERS
    Publication number: 20170360775
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Applicant: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Glutamate agents in the treatment of mental disorders
    Patent number: 8778979
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: July 15, 2014
    Assignee: Yale University
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Glutamate agents in the treatment of mental disorders
    Publication number: 20060270647
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 30, 2006
    Applicant: Yale University
    Inventors: Vladimir Coric, John Krystal, Gerard Sanacora